Nafamostat甲磺酸盐是广谱的丝氨酸蛋白酶抑制剂,血管舒缓素抑制剂,能抑制血液凝固,还是潜在的补体抑制剂。
Nafamostat mesylate, a synthetic serine protease inhibitor, is an anticoagulant.
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Sundaram S, et al. Thromb Haemost, 1996, 75(1), 76-82.
[2] Katsuno, G., et al. 2005. J. Pharmacol. Sci. 98: 463-466.
[3] Choi, C.W., et al. 2009. Gastrointest. Endosc. 69: e11-e18.
[4] Inose, K., et al. 1997. Nephron. 75: 420-425.
分子式 C21H25N5O8S2 |
分子量 539.58 |
CAS号 82956-11-4 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO >10 mg/mL |
Water 25 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT01761994 | Acute Kidney Injury | Drug: Anticoagulation with nafamostat mesilate | Yonsei University|SK Chemicals Co.,Ltd. | Phase 4 | 2007-09-01 | 2013-01-03 |
NCT02478242 | Acute Kidney Injury | Drug: Nafamostat mesilate|Drug: Normal saline | Kyungpook National University | Phase 4 | 2010-07-01 | 2015-06-22 |
NCT01001403 | Liver Transplantation|Postreperfusion Syndrome | Drug: Nafamostat|Drug: Normal saline | Seoul National University Hospital | Phase 4 | 2009-03-01 | 2010-05-04 |
NCT01486485 | Acute Kidney Injury | Drug: heparinized saline priming group|Drug: nafamostat infusion after heparinized saline priming | Seoul National University Hospital|SK Chemicals Co.,Ltd. | Phase 3 | 2012-03-01 | 2013-02-18 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们